Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.
Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Awan AM, Weichselbaum RR, Rondelli D. Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41.
PMID: 25234438
Oxygen-Guided Radiation Therapy.
Epel B, Maggio MC, Barth ED, Miller RC, Pelizzari CA, Krzykawska-Serda M, Sundramoorthy SV, Aydogan B, Weichselbaum RR, Tormyshev VM, Halpern HJ. Oxygen-Guided Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 03 15; 103(4):977-984.
PMID: 30414912
Increased dose near the skin due to electromagnetic surface beacon transponder.
Ahn KH, Manger R, Halpern HJ, Aydogan B. Increased dose near the skin due to electromagnetic surface beacon transponder. J Appl Clin Med Phys. 2015 May 08; 16(3):4930.
PMID: 26103472
AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging.
Aydogan B, Li J, Rajh T, Chaudhary A, Chmura SJ, Pelizzari C, Wietholt C, Kurtoglu M, Redmond P. AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging. Mol Imaging Biol. 2010 Oct; 12(5):463-7.
PMID: 20237857
A novel functional CT contrast agent for molecular imaging of cancer.
Li J, Chaudhary A, Chmura SJ, Pelizzari C, Rajh T, Wietholt C, Kurtoglu M, Aydogan B. A novel functional CT contrast agent for molecular imaging of cancer. Phys Med Biol. 2010 Aug 07; 55(15):4389-97.
PMID: 20647599
Validation of temporal optimization effects for a single fraction of radiation in vitro.
Altman MB, Stinauer MA, Javier D, Smith BD, Herman LC, Pytynia ML, Aydogan B, Pelizzari CA, Chmura SJ, Roeske JC. Validation of temporal optimization effects for a single fraction of radiation in vitro. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):1240-6.
PMID: 19857787
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy.
Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC, Aydogan B, Chmura SJ. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009 Nov; 93(2):298-301.
PMID: 19717198
Characterization of a novel phantom for three-dimensional in vitro cell experiments.
Altman MB, Vesper BJ, Smith BD, Stinauer MA, Pelizzari CA, Aydogan B, Reft CS, Radosevich JA, Chmura SJ, Roeske JC. Characterization of a novel phantom for three-dimensional in vitro cell experiments. Phys Med Biol. 2009 Mar 07; 54(5):N75-82.
PMID: 19182327
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7.
PMID: 17996390
Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Zhu H, Zakeri K, Vaida F, Carmona R, Dadachanji KK, Bair R, Aydogan B, Hasan Y, Yashar CM, Mell LK. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy. J Med Imaging Radiat Oncol. 2015 Jun; 59(3):386-93; quiz 394.
PMID: 25828068